Understanding an Emerging Concept of Triple Negative Breast Cancer (TNBC) at Molecular Level: A Mortal Blow. PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Understanding an Emerging Concept of Triple Negative Breast Cancer (TNBC) at Molecular Level: A Mortal Blow. PDF full book. Access full book title Understanding an Emerging Concept of Triple Negative Breast Cancer (TNBC) at Molecular Level: A Mortal Blow. by Dr. Hakim. K. Saboowala. Download full books in PDF and EPUB format.
Author: Dr. Hakim. K. Saboowala Publisher: Dr.Hakim Saboowala ISBN: Category : Medical Languages : en Pages : 55
Book Description
Understanding an Emerging Concept of Triple Negative Breast Cancer (TNBC) at Molecular Level: A Mortal Blow. Breast cancers are commonly associated with a high incidence and a high mortality rate in the female population worldwide. One of the most controversial women malignancies, triple negative breast cancers (TNBCs) are critically overviewed, being focused on data useful in clinical practice or to improve the therapy and patients survival. TNBCs “choose” young women and its “kiss” is, unfortunately is a “mortal blow” in most cases. Currently, few sparse data are available in literature concerning the origins of TNBC. Vasculogenic mimicry detected in TNBCs, seems to be determined by a population of CD133+ cells and may be stimulated by different pharmacological agents such sunitinib. Despite the fact that TNBCs do not usually metastasize through the lymphatic pathways, TNBCs may be characterized by lymphatic invasion and by an increased lymphatic microvascular density(MVD). If TNBCs treatment depends on the molecular profile of the tumour, the same statement may be postulated for TNBCs metastasis. · Whether metastases have a similar phenotype as the primary tumour remains an enigma. Therefore, it is attempted in this E-Booklet to highlight the question which remains to be investigated further: ‘Could TNBC be subject to a standardized, unanimously accepted therapeutic strategy or is it strictly subclass- dependent?’ along with relevant Illustrations for better understanding. …Dr. H. K. Saboowala. M.B.(Bom) .M.R.S.H.(London)
Author: Dr. Hakim. K. Saboowala Publisher: Dr.Hakim Saboowala ISBN: Category : Medical Languages : en Pages : 55
Book Description
Understanding an Emerging Concept of Triple Negative Breast Cancer (TNBC) at Molecular Level: A Mortal Blow. Breast cancers are commonly associated with a high incidence and a high mortality rate in the female population worldwide. One of the most controversial women malignancies, triple negative breast cancers (TNBCs) are critically overviewed, being focused on data useful in clinical practice or to improve the therapy and patients survival. TNBCs “choose” young women and its “kiss” is, unfortunately is a “mortal blow” in most cases. Currently, few sparse data are available in literature concerning the origins of TNBC. Vasculogenic mimicry detected in TNBCs, seems to be determined by a population of CD133+ cells and may be stimulated by different pharmacological agents such sunitinib. Despite the fact that TNBCs do not usually metastasize through the lymphatic pathways, TNBCs may be characterized by lymphatic invasion and by an increased lymphatic microvascular density(MVD). If TNBCs treatment depends on the molecular profile of the tumour, the same statement may be postulated for TNBCs metastasis. · Whether metastases have a similar phenotype as the primary tumour remains an enigma. Therefore, it is attempted in this E-Booklet to highlight the question which remains to be investigated further: ‘Could TNBC be subject to a standardized, unanimously accepted therapeutic strategy or is it strictly subclass- dependent?’ along with relevant Illustrations for better understanding. …Dr. H. K. Saboowala. M.B.(Bom) .M.R.S.H.(London)
Author: Xiyun Deng Publisher: World Scientific ISBN: 9813277777 Category : Medical Languages : en Pages : 247
Book Description
Triple-negative breast cancer (TNBC) represents a challenge clinically due to the lack of actionable targets coupled with an aggressive disease course and a worse prognosis compared to other breast cancer subtypes. This book covers aspects of TNBC ranging from epidemiology, biology, molecular classification, to currently available and potentially new therapeutic options for TNBC. This book contains a range of recommended resources, including recent reviews, schematic illustrations, and information for patients with TNBC. Individuals including researchers and educators, practitioners, pharmaceutical professionals, patients as well as their family members will find this book useful.
Author: Pravin Kendrekar Publisher: John Wiley & Sons ISBN: 3527841172 Category : Medical Languages : en Pages : 325
Book Description
Drug and Therapy Development for Triple Negative Breast Cancer The first comprehensive and up-to-date compilation of modern diagnostic and treatment methods for triple negative breast cancer In Drug and Therapy Development for Triple Negative Breast Cancer, a team of distinguished practitioners delivers an in-depth and authoritative discussion of contemporary methods for treating triple negative breast cancer (TNBC). The editors have included material that covers its molecular causes, initial detection, diagnostic tools, treatment procedures, pharmacology, and new and experimental therapies—including nanotherapeutics and photothermal therapies. As the first comprehensive compilation of modern treatment methods for TNBC, this reference is an unmatched source of information about current and future treatment approaches, including machine learning methods for earlier detection and more accurate diagnosis. Readers will also find: A thorough introduction to HER receptors in breast cancers Comprehensive explorations of the etiology and therapy of hormone receptor-positive breast cancer and the early-stage diagnosis of breast cancer Application of artificial intelligence to breast cancer diagnosis New insights on the role of DNA replication stress and genome instability in breast cancer Perfect for medicinal and pharmaceutical chemists, Drug and Therapy Development for Triple Negative Breast Cancer will also benefit oncologists and professionals working in the pharmaceutical industry or in hospital settings.
Author: Katarzyna Rygiel Publisher: Bentham Science Publishers ISBN: 9815196030 Category : Medical Languages : en Pages : 263
Book Description
This comprehensive reference is a timely exploration of two vital aspects of triple-negative breast cancer. The volume offers a holistic perspective and empowering patients to navigate the challenges of triple-negative breast cancer (TNBC) with knowledge and confidence. Understanding Ethnic Disparities and Targeted Therapies: This section provides a critical overview of the ethnic disparities and the latest targeted therapies available for patients facing advanced or metastatic triple-negative breast cancer (TNBC). Empowering Patients and Enhancing Communication: This section dives into the essential role of patient education, empowerment, effective communication with medical teams, and psychological or supportive approaches, providing invaluable insights into managing advanced or metastatic breast cancer (BC). Key Features: Introduces a groundbreaking perspective on the TNBC journey, encouraging patients to view their battle with the disease as an opportunity to leverage modern pharmacological advancements and psychological support for improved outcomes. Bridges the gap between clinical or research-related aspects of BC management and the personal needs and expectations of patients, promoting a more holistic approach. Invites perspectives from a wide range of medical professionals, from oncologists and cardiologists to psychologists and nurses, to engage in open dialogues with patients, offering practical education and crucial support. Provides a wealth of helpful resources (including an appendix) for both patients and their medical caregivers, fostering a comprehensive and supportive approach to managing TNBC. This book is an informative resource for medical professionals, researchers, and patients, who want to understand the complexities of triple-negative breast cancer and apply current knowledge in their clinical and caregiving practice.
Author: Carey K. Anders Publisher: Jones & Bartlett Publishers ISBN: 1449684327 Category : Medical Languages : en Pages : 194
Book Description
Approximately10-20% of breast cancer patients are diagnosed with triple-negative breast cancer. 100 Questions & Answers About Triple Negative Breast Cancer provides authoritative and practical answers to the most common questions asked by patients and their loved ones. This easy-to-read book is a comprehensive guide to the basics of triple negative breast cancer, risk factors and prevention, diagnosis, treatment, survivorship, and life after diagnosis. Written by renowned medical experts on the topic, 100 Questions & Answers About Triple Negative Breast Cancer is an invaluable resource for anyone coping with the physical and emotional turmoil of this challenging type of breast cancer.
Author: Manzoor Ahmad Mir Publisher: Academic Press ISBN: 0323961371 Category : Science Languages : en Pages : 262
Book Description
Combinational Therapy in Triple Negative Breast Cancer discusses TNBC at the molecular level from a holistic approach, focusing on combinational strategies targeting various pathways involved in this specific cancer type. Using a monotherapy for the treatment of cancer, especially high-grade tumors like TNBC, is mostly worthless due to the inherent genetic instability of tumor cells to develop intrinsic and acquired resistance. Combination therapy presents more, or at least the same, effectiveness with lower doses of every single agent and decreases the likelihood of chemoresistance, making it essential to understand for multiple therapy options. The book is a valuable resource for cancer researchers, oncologists, graduate students and members of the biomedical field who are interested in the potential of combinational therapies to treat triple negative breast cancer. - Presents up-to-date and cutting-edge knowledge of Triple negative breast cancer (TNBC) biology, clinical aspects and treatment options - Discusses novel targets and pathways involved in TNBC - Provides insights and approaches for future research on TNBC
Author: Andrew Sulaiman Publisher: ISBN: Category : Languages : en Pages :
Book Description
Triple-negative breast cancer (TNBC) is the most refractory subtype of breast cancer to current treatments and accounts disproportionately for the majority of breast cancer-related deaths. Research has not yet identified specific therapies for TNBC and chemotherapy remains the conventional therapy in the clinic. While conventional chemotherapy regimens have demonstrated success at reducing bulk tumor burden, they have been shown to enrich cancer stem cells (CSCs). CSCs promote chemoresistance, metastasis, heterogeneous tumor regeneration and disease relapse. Owing to tumor plasticity and the conversion between CSC and non-CSC subpopulations development of a strategy capable of inhibiting both non-CSC and CSC subpopulations is crucial for TNBC therapy. In this compilation of my main research projects, several new approaches for the treatment of TNBC were identified which target not only the bulk tumor population but also the CSC populations residing within the tumor: 1. Co-suppression of Wnt, HDAC, and ESR1 using clinically relevant low-dose inhibitors effectively repressed both bulk and CSC subpopulations and converted CSCs to non-CSCs in TNBC cells. 2. Co-inhibition of mTORC1, HDAC, and ESR1 was capable of reducing both bulk and CSC subpopulations as well as the conversion of fractionated non-CSC to CSCs in in a human TNBC xenograft model and hampered tumorigenesis following treatment. 3. Inhibition of Wnt and YAP retarded tumor growth of TNBC cells in either epithelial or mesenchymal states, and both CD44high/CD24low and ALDH+ CSC subpopulations were diminished in a human xenograft model reducing tumorigenicity following treatment.
Author: Yan Cheng Publisher: Frontiers Media SA ISBN: 2832541844 Category : Medical Languages : en Pages : 198
Book Description
Basic scientific background Breast cancer is one of the most common cancer and the most frequent cause of cancer death among women worldwide. Currently, subtyping breast cancers into hormone receptor (HR) positive, human epidermal growth factor receptor-2 overexpressing (HER2+), and triple negative breast cancer (TNBC) is the basis of diagnosing and treating this disease. The main treatment strategies for breast cancer include surgery, endocrine therapy, molecular targeted therapy, chemotherapy, radiotherapy, immunotherapy and gene therapy. However, resistance of breast cancer cells to chemotherapeutic agents, molecular targeted therapies and immunotherapy may occur either intrinsically or de nova, and is often ultimately responsible for treatment failure. Therefore, drug resistance poses a major challenge to breast cancer treatment. Current developments: Drug resistance in breast cancer is a complex clinical condition originating from a wide range of molecular alterations. The development of endocrine therapy resistance is believed to be associated with many cellular changes, such as ESR1 gene mutations, bypassing estrogen signaling pathway and altered tamoxifen metabolism. Meanwhile, changes in immune response, alternation of drug-binding property and downstream pathways are involved in the mechanisms of drug resistance in HER2+ breast cancer. In addition, resistance to chemotherapeutic agents predominantly arises from increased drug efflux and cross resistance. Current studies suggest that treatment strategies and therapeutics have to be designed specifically to each patient in different clinical situations. The use of modern genomic, proteomic and functional analytical techniques has contributed to identify novel genes and signaling networks involved in breast cancer drug resistance. Moreover, the use of high-throughput techniques in combination with bioinformatics and systems biology approaches has aided the interrogation of clinical samples and allowed the identification of molecular signatures and genotypes that predict responses to certain drugs. Despite much progress has been made in the field of breast cancer drug resistance, such as combination therapy and drug-loaded nanoparticles, the complexity and variability of drug resistance mechanism still inevitably lead to the continuous occurrence of drug resistance. Therefore, with the increasing amounts of anti-breast cancer agents, there are now unprecedented opportunities to understand and overcome drug resistance through further research into mechanisms and corresponding strategies, which will help achieve lasting disease control and bring survival benefits to patients with advanced cancer. Papers of interest: The current Research Topic of Frontiers in Pharmacology focuses on publishing Original Research, Review articles and Case Reports focusing on (a) elucidating mechanisms of drug resistance in breast cancer, target mutations, tumor microenvironment, undiscovered genes and signaling pathways; (b) promising drug delivery systems that can enhance the sensitivity of anti- breast cancer agents to various tumors; (c) strategies that can improve patient care during bio-chemotherapeutic treatments; (d) small molecule compounds that are effective against drug-resistant breast tumors (e) biomarkers of chemotherapy resistance in breast cancer patients and (f) in vitro and in vivo models. Guidelines for article of submission: - Authors must stick to the set guidelines for ethical practices by the Frontiers journals. - The main content of the article must have certain innovation and research significance. - The authors should describe the construction method of drug-resistant cell lines when using them for experiments in the article.
Author: Dr. Hakim. K. Saboowala
Author: Dr. Hakim. K. Saboowala
Author: Xiyun Deng
Author: Pravin Kendrekar
Author: Katarzyna Rygiel
Author: Carey K. Anders
Author: Sushma Medikayala
Author: Manzoor Ahmad Mir
Author: Andrew Sulaiman
Author: Xiyun Deng
Author: Yan Cheng